Suephy C Chen

Improving Clinical Trial Recruitment and Outcome Measures in Bullous Pemphigoid · July 1, 2020 - June 30, 2023 Co-Principal Investigator · Awarded by: National Institutes of Health/National Institutes of Arthritis Musculoskeletal and Skin Diseases · $702,000.00 (PI: Feldman, co-I: Chen 1% effort )

Determinants of Implementation for Asynchronous Specialty Telemedicine in Rural Areas · January 27, 2020 - July 1, 2021 Prinicipal Investigator · Awarded by: Health Equity and Rural Outreach Innovation Center (HEROIC) · $45,350.00 (PI: Chen, 1% VA effort)

Emory Pediatric Dermatology Fellowship Support · July 1, 2019 - June 30, 2020 Prinicipal Investigator · Awarded by: Pfizer · $80,000.00 PI: Chen, co-PI: Lawley

Melanoma survivorship needs assessment · June 1, 2019 - May 31, 2020 Co-Principal Investigator · Awarded by: Winship Melanoma Innovation Award · $50,000.00 (co-PI: Chen & Lawson, transferred to Lawson) 6/1/19- 5/31/2020, extended to 11/30/2020

Prevention Study Utilizing Hairdressers for Skin Surveillance · June 1, 2019 - May 31, 2020 Prinicipal Investigator · Awarded by: Winship Melanoma Innovation Award · $33,972.00 (PI: Chen, transferred to Yeung) 6/1/19- 5/31/2020, extended to 12/31/2020

Hierarchy of Reliable Diagnostic Data · June 1, 2019 - May 31, 2020 Prinicipal Investigator · Awarded by: Winship Melanoma Innovation Award · $75,000.00 Hierarchy of Reliable Diagnostic Data (PI: Chen, transferred to Yeung) 6/1/19- 5/31/2020, extended to 12/31/2020

Understanding Cutaneous Immunotherapy-related Adverse Events in Melanoma · July 1, 2018 - December 30, 2020 Prinicipal Investigator · Awarded by: American Cancer Society-Melanoma Research Alliance Pilot Award · $200,000.00 (PI: Chen, transferred to Yeung)

Integration of Standard Dermatology Outcome Measures in Electronic Medical Records to treat Atopic Dermatitis (ISDOM) · January 2, 2018 - June 30, 2019 Prinicipal Investigator · Awarded by: Pfizer · $350,000.00 (PI: Chen, transferred to Swerlick) 01/02/18-6/30/19, extended to 12/31/2020

INCB018424: Vitiligo 211 Phase 2 study · July 1, 2017 Prinicipal Investigator · Awarded by: Incyte (PI: Chen, co-I: Rice; transferred to Chisolm) 7/1/2017

Expansion of the Atlanta TeleDermatology Service · October 1, 2016 - September 30, 2019 Prinicipal Investigator · Awarded by: Veterans Affairs Office of Rural Health Enterprise Wide Initiative extended to 9/30/2020

An open-label study of dupilumab in patients with atopic dermatitis who participated in previous dupilumab clinical trials · June 1, 2016 - 2018 Co-Principal Investigator · Awarded by: Regeneron · $29,999.00 (PI: Rice, co-I: Chen) 1% effort 1 subject

Vertical integration of clinical and pathology images in teledermatology consultations and its effect on the accuracy and timing of diagnosis: A pilot study · May 15, 2016 - July 1, 2018 Prinicipal Investigator · Awarded by: Georgia Society of Dermatology and Dermatologic Surgery/Pfizer · $29,934.00

A phase 3, randomized, double-blinded, placebo-controlled study investigating the efficacy and safety of multiple dupilumab dose regimens administered as monotherapy for maintain treatment response in patients with atopic dermatitis · November 1, 2015 - 2017 Co-Principal Investigator · Awarded by: Regeneron · $17,545.00 (PI: Rice, co-I: Chen) 1% effort 1 subject

A phase 3 confirmatory study investigating the efficacy and safety of dupilumab monotherapy administered to adult patients with moderate-to-severe atopic dermatitis · June 1, 2015 - 2017 Co-Principal Investigator · Awarded by: Regeneron · $21,207.00 (PI: Rice, co-I: Chen) 1% effort 2 subjects

Teaching Global and Rural Skin Health through TeleDermatology: A Pilot Curriculum · 2015 - 2015 Co-Principal Investigator · Awarded by: Emory Center for Faculty Development and Excellence Funds For Innovative Teaching · $3,000.00

Southeast Teledermatology Center Expansion and Innovation · November 1, 2014 - October 1, 2015 Director · Awarded by: VISN 7 Initiative Concept Funding (NATS 14-1175) · $791,000.00

Validation and Mobilization of Pediatric Pruritus Outcome Instruments · September 15, 2014 - January 31, 2018 Prinicipal Investigator · Awarded by: U01AR067169, NIH/NIAMS · $621,096.00 Multiple PI: Chen, James Roberts

A phase-2, multicenter, randomized, double-blinded, placebo-controlled, parallel-group, efficacy and safety study of apremilast (CC10004) in subjects with moderate to severe atopic dermatitis · August 1, 2014 - 2017 Prinicipal Investigator · Awarded by: Celgene Corp · $60,384.00 1% effort 6 subjects

Atlanta TeleDermatology Center of Excellence · January 1, 2014 - December 31, 2014 Director · Awarded by: VISN 7 Initiative Concept Funding (NATS 14-247) · $394,800.00

The Efficacy of Mediation for Treatment of Chronic Pruritus: A Pilot Trial for Eczema Patients · January 1, 2014 - December 31, 2014 Prinicipal Investigator · Awarded by: National Eczema Association · $30,000.00

A randomized, double-blinded, regimen-controlled, phase II, multicenter study to asses the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas · April 13, 2013 - 2017 Prinicipal Investigator · Awarded by: Genentech · $90,000.00 1% effort 5 subjects

A phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular Rosacea · March 1, 2012 - September 30, 2013 Prinicipal Investigator · Awarded by: Galderma · $75,000.00 1% effort 6 subjects

VA Dermatology Mini-Residency Program · October 1, 2011 - February 28, 2014 Director · Awarded by: US Department of Veterans Affairs · $580,000.00

Project SAENet Protocol: International Consortium on Drug Hypersensitivity · July 1, 2011 - September 30, 2014 Co-Principal Investigator · Awarded by: International SAE Consortium Ltd ("SAEC") · $52,500.00

A Phase 2 Pilot Multicenter Sequential Ascending Dose Study to Evaluate the Preliminary Safety Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus · October 1, 2010 - May 31, 2013 Prinicipal Investigator · Awarded by: Celgene Corp · $75,335.00 1% effort 4 subjects

A Randomized Double Blind Placebo Controlled Single Dose, Two Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinic Efficacy of AMG 811 in Subjects with Discoid Lupus Erythematosus · July 1, 2010 - March 31, 2014 Prinicipal Investigator · Awarded by: Amgen · $208,270.00 1% effort 6 subjects

Etanercept and Vascular Function in Psoriasis · June 1, 2010 - July 31, 2014 Co-Principal Investigator · Awarded by: Amgen · $25,144.00 (PI: Quyymi, Co-I: Chen) 1% effort 5 subjects

Comparison of Diagnostic and Biopsy/Referral Sensitivity to Melanoma between Three Groups of Physicians and MelaFind® · June 2010 - June 2014 Prinicipal Investigator · Awarded by: Electo-optical systems · $63,000.00

Phase IV Randomized Study of 2 dose levels of Targretin Capsules in patients with refractory Cutaneous T-Cell Lymphoma · December 1, 2009 - November 30, 2014 Co-Principal Investigator · Awarded by: EISAI · $52,455.00 (PI: Parker, Co-I: Chen) 1% effort 5 subjects

A Randomized Controlled Multidose Multicentre Adaptive Phase II/III Study in Infants with Proliferating Infantile Hemangiomas Requiring Systemic Therapy to Compare Four Regimens of Propanolol (1 or 3 mg/kg/day for 3 to 6 months) to Placebo (Double-Blind) · August 1, 2009 - March 31, 2012 Co-Principal Investigator · Awarded by: PierreFabre · $111,773.00 (PI: Lawley, Co-I Chen) 1% effort 0 subjects

A One Year, Multicenter, Double-Masked, Randomized, Parallel Group Study Assessing the Safety and Efficacy of Once Daily Application of Bimatoprost 0.03% Solution Compared to Vehicle to Treat Hypotrichosis of the Eyelashes from Varied Etiologies · July 1, 2009 - July 31, 2011 Prinicipal Investigator · Awarded by: Allergan · $50,762.00 1% effort 5 subjects

Keratinocyte Carcinoma Chemoprevention (KCC) Trial · May 1, 2009 - April 30, 2014 Site Prinicipal Investigator · Awarded by: VA Cooperative Study Program (CSP#562) · $92,000.00 $92,000.00 (year 1)

Division of Cancer Prevention and Control · September 1, 2008 - August 31, 2012 Prinicipal Investigator · Awarded by: Centers for Disease Control and Prevention (IPA) · $25,838.00 "Dermatoepidemiologist for Skin Cancer Research" PI: Chen 20%

ESPRIT: A 10-year post marketing Observational registry of HUMIRA in adult patients with chronic plaque psoriasis · September 1, 2008 - September 30, 2014 Co-Principal Investigator · Awarded by: Abbott · $108,070.00 (PI: Parker; Co-I: Chen) 1% effort 10 subjects

PSUNRISE: A Multicenter, Open Label Study to Assess the Efficacy and Safety of Infliximab Therapy in Patients with Plaque Psoriasis Who Had an Inadequate Response to Etanercept · November 1, 2007 - April 30, 2010 Prinicipal Investigator · Awarded by: Centocor · $43,787.00 1% effort 3 subjects

The Economic Burden of Cutaneous Disease in Ichthyosis Patients and Families · November 1, 2007 - March 31, 2009 Prinicipal Investigator · Awarded by: FIRST (Foundation for Ichthyosis and Related Skin Types) · $49,284.00 PI: Chen, 5%

Single Agent Phase II Study of Forodesine (BCX 1777) in the Treatment of Cutaneous T-Cell Lymphoma · July 1, 2007 - November 30, 2010 Co-Principal Investigator · Awarded by: BioCryst · $59,610.00 (PI: Parker, Co-I: Chen) 1% effort 3 subjects

Veteran Impact of Chronic Pruritus: The skin equivalent of chronic pain · July 1, 2007 - September 30, 2011 Prinicipal Investigator · Awarded by: Rehab Research and Development Merit Review (Project Number F45291) · $364,300.00 PI Chen: 40%

A prospective 2-year longitudinal study to assess for miconazole resistance in candida with repeated treatment courses of 0.25 % miconazole nitrate ointment in neonates and infants up to 1 year of age ... · June 7, 2007 - June 7, 2009 Prinicipal Investigator · Awarded by: Barrier · $15,772.00 A prospective 2-year longitudinal study to assess for miconazole resistance in candida with repeated treatment courses of 0.25 % miconazole nitrate ointment in neonates and infants up to 1 year of age with recurrent moderate to severe diaper dermatitis complicated by cutaneous candidiasis 1% effort 3 subjects

A double blind randomized multi-center pilot study to evaluate the efficacy and safety of etanercept 50 mg SQ twice weekly in the treatment of lichen planus · March 9, 2007 - March 31, 2009 Prinicipal Investigator · Awarded by: Amgen · $21,590.00 1% effort 2 subjects

Observational post-marketing safety surveillance registry of Enbrel for the treatment of psoriasis (OBSERVE) · November 28, 2006 - November 30, 2011 Prinicipal Investigator · Awarded by: Amgen · $23,738.00 1% effort 10 subjects

A pilot study to evaluate the safety and efficacy of diclofenac sodium 3% gel for the treatment of disseminated superficial actinic porokeratosis · November 2006 - October 2007 Prinicipal Investigator · Awarded by: Bradley · $9,375.00 1% effort 3 subjects

Raptiva epidemiology study of psoriasis outcomes and safety events (RESPONSE) · August 1, 2006 - 2010 Prinicipal Investigator · Awarded by: Genentech · $59,000.00 1% effort 10 subjects

APPLES: A prospective pediatric longitudinal evaluation to assess the long term safety of Tacrolimus ointment for the treatment of AD · March 30, 2006 - 2018 Co-Principal Investigator · Awarded by: Astellas · $57,720.00 (PI: Spraker, Co-I: Chen) 1% effort 10 subjects

A Phase 3, Long Term Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis · January 16, 2006 - January 31, 2008 Prinicipal Investigator · Awarded by: Astellas · $83,845.00 1% effort 5 subjects

A Phase IV open-label study to evaluate the safety and efficacy of 1mg/kg SQ administered efaluzimab in adults with bullous pemphigoid as a steroid sparing adjunctive treatment · 2006 - December 2007 Prinicipal Investigator · Awarded by: Genentech (PI: Chen) Drug Support Only

A continuation clinical trial of oral L-001079038 in advance cancers · October 10, 2005 - 2010 Co-Principal Investigator · Awarded by: Merck · $48,056.00 (PI: Parker, Co-I: Chen) 1% effort 4 subjects

RESPONSE: Raptiva Epidemiological Study of Psoriasis Outcomes and Safety Events in patients with chronic moderate-to-severe plaque psoriasis · September 1, 2005 - March 31, 2012 Prinicipal Investigator · Awarded by: Genentech · $78,280.00 1% effort 10 subjects

A double blinded randomized 2 dose parallel group multi-center clinical trial of HUMAX-CD4 ... · May 23, 2005 - 2013 Co-Principal Investigator · Awarded by: GenMab · $46,502.00 A double blinded randomized 2 dose parallel group multi-center clinical trial of HUMAX-CD4 , a fully human monoclonal anti-CD4 antibody in patients with mycosis fungoides (StageIB-IVB) who are refractory or intolerant to Targretin and 1 other standard therapy (PI: Parker, Co-I: Chen) 1% effort 3 subjects

ATLAS: Assessment and Tracking of Long Term Alefacept Safety · April 29, 2005 - 2013 Prinicipal Investigator · Awarded by: Biogen · $27,750.00 1% effort 5 subjects

A Phase 3 Randomized, Double-Blinded Study Comparing Twice Daily Tacrolimus Cream 0.3% versus Cream Vehicle in the Treatment of Atopic Dermatitis in Pediatric Subjects · December 23, 2004 - December 31, 2005 Co-Principal Investigator · Awarded by: Fujisawa · $42,062.00 (PI: Spraker,Co-I: Chen) 1% effort 5 subjects

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Once Daily 0.3% Tacrolimus Gel versus Gel Vehicle in the Treatment of Psoriasi · December 1, 2004 - December 31, 2005 Prinicipal Investigator · Awarded by: Fujisawa · $74,812.00 s 1% effort 10 subjects

No. 78 Phase IIb Clinical Trial of a topical agent to prevent Non-Melanoma Skin Cancer in organ allograft recipients · November 2004 - February 2006 Site Prinicipal Investigators · Awarded by: National Cancer institute · $84,825.00

A Phase IIB multicenter clinical trial of oral SAHA in advanced CTCL · October 2004 - December 2007 Co-Principal Investigator · Awarded by: Merck · $60,070.00 (PI: Parker,Co-I: Chen) 1% effort 5 subjects

Efficacy and Safety of BAL 4079 in the treatment of severe chronic hand dermatitis refractory to topical therapy · September 1, 2004 - August 30, 2006 Prinicipal Investigator · Awarded by: Basilea · $7,631.00 (Sponsor discontinued study) 1% effort 0 subjects

EASE: A multi-center open-label prospective study to evaluate the efficacy and safety of etanercept in the treatment of subjects with psoriasis · July 15, 2004 - June 30, 2006 Prinicipal Investigator · Awarded by: Amgen 20030115 · $90,050.00 1% effort 10 subjects

Prospective randomized double-blinded placebo controlled parallel group multi-center 52-week trial · July 12, 2004 - August 1, 2006 Prinicipal Investigator · Awarded by: Aspreva · $9,688.00 Prospective randomized double-blinded placebo controlled parallel group multi-center 52-week trial to assess the efficacy and safety of adjunct mycofenolate mofetil to achieve remission with reduced corticosteroids in subjects with active pemphigus vulgaris 1% effort 1 subject

A Multicenter international observational study of the long term safety of Infliximab (RESULTS) · March 10, 2004 - December 31, 2009 Prinicipal Investigator · Awarded by: Centocor · $16,100.00 1% effort 2 subjects

Burden of disease in Sturge-Weber patients and families · January 1, 2004 - January 1, 2005 Prinicipal Investigator · Awarded by: Sturge-Weber Foundation · $20,000.00

A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab ... · January 2004 - September 2005 Prinicipal Investigator · Awarded by: Genentech · $46,716.00 A phase IIIb, open-label, multicenter study to evaluate the safety of 1.0mg/kg subcutaneously administered Efalizumab in adults with moderate to severe plaque psoriasis, including those who are receiving concomitant anti-psoriatic therapies or have recently transitioned from systemic therapies 1% effort 6 subjects

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial ... · December 19, 2003 - December 30, 2005 Prinicipal Investigator · Awarded by: Centocor · $73,125.00 A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Subjects with Plaque-type Psoriasis 1% effort 3 subjects

An Open Label, Long Term Extension Study to Assess the Safety of Etanercept in the treatment of Psoriasis in Adult Subjects · August 6, 2003 - August 31, 2005 Prinicipal Investigator · Awarded by: Amgen · $46,716.00 1% effort 5 subjects

The Toyota Skin Cancer Prevention Fund · April 15, 2003 - June 2010 Co-Principal Investigator · Awarded by: Toyota · $105,000.00 Co-PI: Chen 5%

A Phase II Study of Medi-507: A Long-term Safety followup study of psoriasis patients who have received Medi-507 · February 13, 2003 - March 31, 2008 Co-Principal Investigator · Awarded by: MedImmune MI-CP085 · $62,745.00 (PI: McCall, Co-I: Chen) 1% effort 3 subjects

Cutaneous Oncology Outcomes Research · January 1, 2003 - December 31, 2003 Prinicipal Investigator · Awarded by: David Martin Carter Research Scholar Award, American Skin Association · $50,000.00

Virtual Dermatopathology: A Method for Teaching Dermatopathology via the Internet · January 1, 2003 - December 31, 2004 Prinicipal Investigator · Awarded by: Sulzberger Institute for Dermatologic Education · $29,600.00

Mohs Surgery vs. Standard Excision: A cost-effectiveness analysis · July 1, 2002 - December 31, 2004 Prinicipal Investigator · Awarded by: Health Services Research Grant , American Skin Association · $15,000.00

A Phase II Randomized, Double-Blind Study ... · April 1, 2002 - March 31, 2003 Co-Principal Investigator · Awarded by: Fujisawa · $73,125.00 A Phase II Randomized, Double-Blind Study to Evaluate the Dosing Concentration and Application Frequency of Tacromilus Gel in the Treatment of Mild to Moderate Psoriasis in Pediatric and Adult Subjects (PI: McCall, Co-I: Chen) 1% effort 3 subjects

A Phase 2, Randomized, Double-Blind Study of 0.01% and 0.03% Tacrolimus Cream Versus Cream Vehicle in the Treatment of Mild to Moderate Atopic Dermatitis in Adults · January 29, 2002 - November 30, 2003 Co-Principal Investigator · Awarded by: Fujisawa · $15,000.00 (PI: McCall,Co-I: Chen) 1% effort 5 subjects $15,000

Teledermatology vs. Face to Face Evaluation: Quality of Life Outcomes · January 1, 2002 - September 21, 2004 Consultant · Awarded by: Brooks Army Medical Center, Department of Defense · $11,520.00

Cost-Effective Melanoma Care: Generalist vs. Specialist · September 24, 2001 - July 1, 2007 Prinicipal Investigator · Awarded by: K23AR 02185-01A1, NIH · $522,025.00 (PI: Chen 90%)

A Phase II Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Finding, Safety and Efficacy Study of IDEC-114 ... · July 25, 2001 - July 25, 2002 Co-Principal Investigator · Awarded by: Idec · $127,608.00 A Phase II Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Finding, Safety and Efficacy Study of IDEC-114 (a PRIMATIZED Monoclonal Antibody against CD80) in Patients with Moderate to Severe Plaque Psoriasis (PI: McCall, Co-I: Chen) 1% effort 5 subjects

HEALing of Ischemic Foot Ulcers with Cilostazol Trial · July 1, 2001 - June 1, 2006 Co-Principal Investigator · Awarded by: Otsuka Pharmaceuticals, Inc · $31,515.00 (PI: Weintraub, Co-PI: Chen,10%) 15 subjects

Cost-effectiveness of Melanoma Screening and Management: Generalists vs. Dermatologists · July 2001 - June 2002 Prinicipal Investigator · Awarded by: Dermatology Foundation · $20,000.00

Vehicle -Controlled, Double -Blind Study to Assess the Safety and Efficacy of Imiquiod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma Protocol # 1408-IMIQ · January 23, 2001 - May 31, 2002 Co-Principal Investigator · Awarded by: 3M · $72,025.00 Vehicle -Controlled, Double -Blind Study to Assess the Safety and Efficacy of Imiquiod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma Protocol # 1408-IMIQ (PI: Weintraub, Co-PI: Chen) 1% effort 12 subjects

"Prevalence and Cost-effective melanoma management in veterans" · 2001 - 2003 Prinicipal Investigator · Awarded by: Career Development Award, Network 7 VISN Veterans Administration · $78,000.00

Cost-Effectiveness Melanoma Care: Gatekeeper or Direct Access · 2001 - 2002 Prinicipal Investigator · Awarded by: Project and Feasibility Grant (#P30AR42687), NIH Emory Skin Disease Research Center · $20,000.00

A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis · September 1, 2000 - April 30, 2002 Co-Principal Investigator · Awarded by: MedImmune MI-CP062 · $55,480.00 A phase I multiple-dose, dose-escalation study to evaluate the safety of MEDI-507, a humanized monoclonal antibody that binds to the CD2 receptor, administered by subcutaneous injection to patients with plaque psoriasis (PI: McCall, Co-I: Chen) 1% effort 3 subjects

A Phase II, Randomized, Placebo-Controlled, Double-Blind Study of MEDI-507, a Humanized Monoclonal Antibody that Binds to the CD2 Receptor, Administered by Subcutaneous Injection to Adults with Plaque Psoriasis, Protocol IM-CP082 · August 1, 2000 - January 31, 2001 Co-Principal Investigator · Awarded by: MedImmune · $133,701.00 (PI: McCall, Co-I: Chen) 1% effort 3 subjects

An open-label, multidose, multicenter study to evaluate the safety and tolerability of subcutaneously administered anti-CD11a in adults with plaque psoriasis previously treated with anti-CD11a or placebo · February 1, 2000 - December 31, 2002 Co-Principal Investigator · Awarded by: Genentech · $42,503.00 (PI: McCall, Co-I: Chen) 1% effort 6 subjects

Cost-effectiveness of Melanoma Screening and Management: Generalists vs. Dermatologists · 2000 - 2003 Prinicipal Investigator · Awarded by: Health Care Policy Clinical Career Development Award, Dermatology Foundation · $110,000.00 returned when K23 awarded

A Web-based Dermatology Teaching Curriculum for Medical Students at Emory University · 2000 - 2001 Co-Principal Investigator · Awarded by: Teaching Innovation Award, Emory University · $5,000.00

A phase II, randomized, parallel group, efficacy and safety study ... · January 1, 1999 - June 30, 2000 Co-Principal Investigator · Awarded by: Merck · $30,000.00 A phase II, randomized, parallel group, efficacy and safety study of BMS-234303 1%, 2% versus its vehicle QD (Double Blind), mioxidil 5% versus its vehicle BID (Double Blind) and BMS-234303 1% and 2% QD versus minoxidil 5% BID (Single Blind) in adult males with androgenetic alopecia (PI: McCall, Co-I: Chen) 1% effort <10 subjects

Unrestricted Educational Grant for Outcomes Research in Dermatology · 1999 - 1999 Prinicipal Investigator · Awarded by: Connectics, Inc. · $20,000.00

A 6-month parallel group, randomized, investigator-blind, placebo-controlled, multicenter proof of concept trial comparing the efficacy of E25 to that of placebo in the treatment of moderate to severe atopic dermatitis in subjects 6-16 · August 1, 1998 - January 31, 2002 Co-Principal Investigator · Awarded by: Novartis · $30,000.00 (PI: McCall, Co-I: Chen) 1% effort <10 subjects

A Prospective, Multi-center, Open-label, Non-comparative Study to Assess the Efficacy and Safety of Neoral Soft Gelatin Capsules in the Treatment of Black Subjects with Severe Recalcitrant Plaque-type Psoriasis · May 1998 - December 1999 Co-Principal Investigator · Awarded by: Novartis · $100,000.00 (PI: McCall, Co-I: Chen) 1% effort <10 subjects

National Research Service Award (#T32 HS00028) · 1997 - 2000 Prinicipal Investigator · Awarded by: Agency for Healthcare Research and Quality (PI: Garber, Recipient: Chen) Salary support

National Research Service Award (#T2-HS000028) · 1997 - 2000 PI: Garber; Recipient: Chen · Awarded by: Agency for Healthcare Research and Quality Salary support

External Relationships

Emory University School of Medicine

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.